OMEROS CORP
About OMEROS CORP
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2020
- $73.8M
- Net income
- -$3.4M
- Total assets
- $325.6M
- Market cap
- $708.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating income
- -$122.8M
- Income tax
- $2.0M
- Net income
- -$3.4M
- EPS (basic)
- $-0.05
- EPS (diluted)
- $-0.05
Balance sheet
- Total assets
- $325.6M
- Current assets
- $215.7M
- Total liabilities
- $446.9M
- Current liabilities
- $78.1M
- Shareholders’ equity
- -$121.2M
Cash flow
- Operating cash flow
- -$116.1M
- Investing cash flow
- $164.5M
- Financing cash flow
- -$42.2M
- Net cash flow
- $6.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $708.6M
- EPS (diluted)
- $-0.05
- Shares outstanding
- 71.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 8, 2009
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $3.4M in FY2020.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review OMEROS CORP.
Write a review
News about OMEROS CORP
News & sentiment via Polygon.io
